News
Public · Published
AbbVie lifts annual profit forecast as immunology drugs continue to fuel growth
AbbVie raised its annual profit forecast after third-quarter results beat Wall Street expectations, helped by newer immunology drugs and its neuroscience portfolio, which offset declining sales of former top seller Humira. Shares slipped over 1% in premarket trading.
Published:
Updated:
What happened
AbbVie raised its annual profit forecast after third-quarter results beat Wall Street expectations, helped by newer immunology drugs and its neuroscience portfolio, which offset declining sales of former top seller Humira. Shares slipped over 1% in premarket trading.
Confirmed
Global impact / market context
The forecast increase signals profit is holding up as sales shift from Humira, which lost US patent protection in 2023, to Skyrizi and Rinvoq. That replacement matters because investors are judging whether newer drugs can keep revenue and cash available growing.
Analyst inference
AbbVie shares are up about 27% this year and closed at a record $290.79 on Thursday. Analysts called the quarterly beat modest after that run, so the debate over the drug pipeline and business development beyond immunology is likely to continue.
Analyst inference
What to watch
- Skyrizi sales reached $5.78 billion for the quarter, up 22.7% from a year earlier and above Wall Street estimates of $5.75 billion, according to LSEG data. Confirmed
- Watch whether AbbVie's pipeline and business development efforts beyond immunology deliver new products, since analysts expect debate on this to persist. Proposed
- Track Humira's decline against Skyrizi and Rinvoq growth, because the pace of that handover affects future revenue, profit per sale and the company's ability to fund research. Analyst inference
Evidence
- Original source link unavailable